 AIM ImmunoTech Inc NYSE:AIM reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus COVID-19 had shown no severe adverse events and that the drug was generally well tolerated. The trial saw 40 healthy subjects receive either Ampligen or a placebo, with the Ampligen given at four escalating dosages across four cohorts, to a maximum level of 1,250 micrograms. 